An MS disease-modifying therapy
(DMT) is often recommended for people diagnosed with CIS that is considered likely to progress to clinically definite MS (CDMS), with the goal of delaying a second attack. There are several DMTs approved by the US Food and Drug and Administration (FDA) for relapsing forms of MS, which includes CIS.
Early and ongoing treatment with disease-modifying therapy is supported by the MS Coalition
which includes the National MS Society. This evidence-based Consensus on Disease-Modifying Therapies
(.pdf) may be useful when discussing treatment options with your healthcare provider and advocating with insurers for access and coverage.